Inhibition of BACE1 for therapeutic use in Alzheimer's disease

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 6, 2010, Pages 618-628

  Luo, Xiaoyang ^a   Yan, Riqiang ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Amyloid plaques; Aspartyl protease; BACE1; Drug discovery

Indexed keywords

ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; ENZYME INHIBITOR; SECRETASE;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG DESIGN; ENZYMOLOGY; HUMAN; METABOLISM;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; ASPARTIC ACID PROTEASES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS;

EID: 77956048697     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Selkoe DJ. Alzheimer disease: mechanistic un-derstanding predicts novel therapies. Ann Intern Med 2004; 140: 627-638.
2. Tanzi RE and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a ge-netic perspective. Cell 2005; 120: 545-555.
3. Hutton M, Perez-Tur J and Hardy J. Genetics of Alzheimer's disease. Essays Biochem 1998; 33: 117-131.
4. Younkin SG. The role of A beta 42 in Alzheimer's disease. J Physiol Paris 1998; 92: 289-292.
5. Hardy J. Amyloid double trouble. Nat Genet 2006; 38: 11-12.
6. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS and Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261: 6084-6089.
7. Ihara Y, Nukina N, Miura R and Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem 1986; 99: 1807-1810.
8. LaFerla FM and Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 2005; 11: 170-176.
9. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Ama-rante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G and Citron M. Beta-secretase cleav-age of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-741.
10. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL and Gurney ME. Mem-brane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999; 402: 533-537.
11. Sinha S, Anderson JP, Barbour R, Basi GS, Cac-cavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L and John V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999; 402: 537-540.
12. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C and Christie G. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999; 14: 419-427.
13. Lin X, Koelsch G, Wu S, Downs D, Dashti A and Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A 2000; 97: 1456-1460.
14. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Mar-tin L, Louis JC, Yan Q, Richards WG, Citron M and Vassar R. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001; 4: 231-232.
15. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL and Wong PC. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 2001; 4: 233-234.
16. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappen-man KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S and McConlogue L. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10: 1317-1324.
17. Farzan M, Schnitzler CE, Vasilieva N, Leung D and Choe H. BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci U S A 2000; 97: 9712-9717.
18. Yan R, Munzner JB, Shuck ME and Bienkowski MJ. BACE2 functions as an alternative alpha-secretase in cells. J Biol Chem 2001; 276: 34019-34027.
19. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D'Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P and De Strooper B. Phenotypic and biochemical analyses of BACE1-and BACE2-deficient mice. J Biol Chem 2005; 280: 30797-30806.
20. Shi XP, Chen E, Yin KC, Na S, Garsky VM, Lai MT, Li YM, Platchek M, Register RB, Sardana MK, Tang MJ, Thiebeau J, Wood T, Shafer JA and Gardell SJ. The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. J Biol Chem 2001; 276: 10366-10373.
21. Hong L, Turner RT, 3rd, Koelsch G, Shin D, Ghosh AK and Tang J. Crystal structure of me-mapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. Biochemistry 2002; 41: 10963-10967.
22. Haniu M, Denis P, Young Y, Mendiaz EA, Fuller J, Hui JO, Bennett BD, Kahn S, Ross S, Burgess T, Katta V, Rogers G, Vassar R and Citron M. Characterization of Alzheimer's beta-secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem 2000; 275: 21099-21106.
23. Bennett BD, Denis P, Haniu M, Teplow DB, Kahn S, Louis JC, Citron M and Vassar R. A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta-secretase. J Biol Chem 2000; 275: 37712-37717.
24. Capell A, Steiner H, Willem M, Kaiser H, Meyer C, Walter J, Lammich S, Multhaup G and Haass C. Maturation and pro-peptide cleavage of beta-secretase. J Biol Chem 2000; 275: 30849-30854.
25. Benjannet S, Elagoz A, Wickham L, Mamarbachi M, Munzer JS, Basak A, Lazure C, Cromlish JA, Sisodia S, Checler F, Chretien M and Seidah NG. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodo-main shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem 2001; 276: 10879-10887.
26. Creemers JW, Ines Dominguez D, Plets E, Sern-eels L, Taylor NA, Multhaup G, Craessaerts K, Annaert W and De Strooper B. Processing of beta-secretase by furin and other members of the proprotein convertase family. J Biol Chem 2001; 276: 4211-4217.
27. Costantini C, Ko MH, Jonas MC and Puglielli L. A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. Biochem J 2007; 407: 383-395.
28. Yan R, Han P, Miao H, Greengard P and Xu H. The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta-amyloid precursor protein (APP) substrate. J Biol Chem 2001; 276: 36788-36796.
29. Turner RT, 3rd, Loy JA, Nguyen C, Deva-samudram T, Ghosh AK, Koelsch G and Tang J. Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity. Biochemistry 2002; 41: 8742-8746.
30. Tomasselli AG, Qahwash I, Emmons TL, Lu Y, Leone JW, Lull JM, Fok KF, Bannow CA, Smith CW, Bienkowski MJ, Heinrikson RL and Yan R. Employing a superior BACE1 cleavage sequence to probe cellular APP processing. J Neurochem 2003; 84: 1006-1017.
31. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L and Selkoe DJ. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1995; 1: 1291-1296.
32. Koo EH and Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 1994; 269: 17386-17389.
33. Vassar R, Kovacs DM, Yan R and Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 2009; 29: 12787-12794.
34. Murayama KS, Kametani F, Saito S, Kume H, Akiyama H and Araki W. Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta-protein. Eur J Neurosci 2006; 24: 1237-1244.
35. He W, Lu Y, Qahwash I, Hu XY, Chang A and Yan R. Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med 2004; 10: 959-965.
36. Walter J, Fluhrer R, Hartung B, Willem M, Kaether C, Capell A, Lammich S, Multhaup G and Haass C. Phosphorylation regulates intracellular trafficking of beta-secretase. J Biol Chem 2001; 276: 14634-14641.
37. Huse JT, Pijak DS, Leslie GJ, Lee VM and Doms RW. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem 2000; 275: 33729-33737.
38. He X, Chang WP, Koelsch G and Tang J. Me-mapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2. FEBS Lett 2002; 524: 183-187.
39. Shiba T, Kametaka S, Kawasaki M, Shibata M, Waguri S, Uchiyama Y and Wakatsuki S. Insights into the phosphoregulation of beta-secretase sorting signal by the VHS domain of GGA1. Traffic 2004; 5: 437-448.
40. von Arnim CA, Tangredi MM, Peltan ID, Lee BM, Irizarry MC, Kinoshita A and Hyman BT. Demon-stration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. J Cell Sci 2004; 117: 5437-5445.
41. He X, Li F, Chang WP and Tang J. GGA proteins mediate the recycling pathway of memapsin 2 (BACE). J Biol Chem 2005; 280: 11696-11703.
42. Wahle T, Prager K, Raffler N, Haass C, Famulok M and Walter J. GGA proteins regulate retro-grade transport of BACE1 from endosomes to the trans-Golgi network. Mol Cell Neurosci 2005; 29: 453-461.
43. Koh YH, von Arnim CA, Hyman BT, Tanzi RE and Tesco G. BACE is degraded via the lysosomal pathway. J Biol Chem 2005; 280: 32499-32504.
44. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen M, Yang SH, Zhong Z, Shen Y, Simpkins JW and Tanzi RE. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 2007; 54: 721-737.
45. Vetrivel KS, Meckler X, Chen Y, Nguyen PD, Sei-dah NG, Vassar R, Wong PC, Fukata M, Kounnas MZ and Thinakaran G. Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. J Biol Chem 2009; 284: 3793-3803.
46. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D and Simons K. Lipids as modulators of proteolytic activity of BACE: in-volvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 2005; 280: 36815-36823.
47. Tun H, Marlow L, Pinnix I, Kinsey R and Samba-murti K. Lipid rafts play an important role in A beta biogenesis by regulating the beta-secretase pathway. J Mol Neurosci 2002; 19: 31-35.
48. Cordy JM, Hussain I, Dingwall C, Hooper NM and Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 2003; 100: 11735-11740.
49. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD and Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 2006; 9: 1520-1525.
50. Willem M, Garratt AN, Novak B, Citron M, Kauf-mann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C and Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science 2006; 314: 664-666.
51. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL and Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizo-phrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A 2008; 105: 5585-5590.
52. De Strooper B, Vassar R and Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6: 99-107.
53. De Strooper B, Saftig P, Craessaerts K, Vander-stichele H, Guhde G, Annaert W, Von Figura K and Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387-390.
54. Li J, Fici GJ, Mao CA, Myers RL, Shuang R, Donoho GP, Pauley AM, Himes CS, Qin W, Kola I, Merchant KM and Nye JS. Positive and negative regulation of the gamma-secretase activity by nicastrin in a murine model. J Biol Chem 2003; 278: 33445-33449.
55. Ma G, Li T, Price DL and Wong PC. APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development. J Neurosci 2005; 25: 192-198.
56. Kopan R and Turner DL. The Notch pathway: democracy and aristocracy in the selection of cell fate. Curr Opin Neurobiol 1996; 6: 594-601.
57. Wolfe MS. Gamma-secretase: structure, function, and modulation for Alzheimer's disease. Curr Top Med Chem 2008; 8: 2-8.
58. Sisodia SS and St George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 2002; 3: 281-290.
59. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC and Tang J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000; 290: 150-153.
60. Shuto D, Kasai S, Kimura T, Liu P, Hidaka K, Hamada T, Shibakawa S, Hayashi Y, Hattori C, Szabo B, Ishiura S and Kiso Y. KMI-008, a novel beta-secretase inhibitor containing a hydroxy-methylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. Bioorg Med Chem Lett 2003; 13: 4273-4276.
61. Kimura T, Shuto D, Hamada Y, Igawa N, Kasai S, Liu P, Hidaka K, Hamada T, Hayashi Y and Kiso Y. Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg Med Chem Lett 2005; 15: 211-215.
62. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabo B, Hashimoto Y, Maruyama K, Tanuma S, Kiso Y and Ishiura S. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein trans-genic and wild-type mice. J Neurochem 2006; 96: 533-540.
63. Hu J, Cwi CL, Smiley DL, Timm D, Erickson JA, McGee JE, Yang HC, Mendel D, May PC, Shapiro M and McCarthy JR. Design and synthesis of statine-containing BACE inhibitors. Bioorg Med Chem Lett 2003; 13: 4335-4339.
64. Tung JS, Davis DL, Anderson JP, Walker DE, Mamo S, Jewett N, Hom RK, Sinha S, Thorsett ED and John V. Design of substrate-based inhibi-tors of human beta-secretase. J Med Chem 2002; 45: 259-262.
65. Tamamura H, Kato T, Otaka A and Fujii N. Synthesis of potent beta-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies. Org Biomol Chem 2003; 1: 2468-2473.
66. Ghosh AK, Kumaragurubaran N, Hong L, Kul-karni SS, Xu X, Chang W, Weerasena V, Turner R, Koelsch G, Bilcer G and Tang J. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem 2007; 50: 2399-2407.
67. Ghosh AK, Kumaragurubaran N, Hong L, Kul-karni S, Xu X, Miller HB, Reddy DS, Weerasena V, Turner R, Chang W, Koelsch G and Tang J. Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett 2008; 18: 1031-1036.
68. Kimura T, Hamada Y, Stochaj M, Ikari H, Na-gamine A, Abdel-Rahman H, Igawa N, Hidaka K, Nguyen JT, Saito K, Hayashi Y and Kiso Y. Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres. Bioorg Med Chem Lett 2006; 16: 2380-2386.
69. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S and Davis JB. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta pro-duction in vivo. J Neurochem 2007; 100: 802-809.
70. Iserloh U, Pan J, Stamford AW, Kennedy ME, Zhang Q, Zhang L, Parker EM, McHugh NA, Favreau L, Strickland C and Voigt J. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor. Bioorg Med Chem Lett 2008; 18: 418-422.
71. Hey JA, Koelsch G, Bilcer G, Jacobs A, Tolar M, Tang J, Ghosh A K, Hsu HH. Single Dose Administration of the β-Secretase Inhibitor CTS21166 (ASP1702) Reduces Plasma Aβ40 in Human Subjects. Presented at the International Conference on Alzheimer's Disease (ICAD), Chi-cago, IL, 2008.
72. Hsu HH, Jacobs A, Yu J, Li A, Koelsch G, Bilcer G, Tolar M, Grove C, Ghosh AK, Tang J, Hey JA. Phase 1 Safety and Pharmacokinetic Profile of Single Doses of CTS21166 (ASP1702) in Healthy Males. Presented at the International Conference on Alzheimer's Disease (ICAD), Chicago, IL, 2008.
73. Yu J, Li A, Koelsch G, Bilcer G, Hsu HH, Jacobs A, Tolar M, Tang J, Ghosh AK, Hey JA. Pharmacokinetic/Pharmacodynamic Analysis of Plasma Aβ40 Reduction in Human Subjects Produced by the β-Secretase Inhibitor CTS21166 (ASP1702). Presented at the International Conference on Alzheimer's Disease (ICAD), Chicago, IL, 2008.
74. Koelsch G, Tang J, Ghosh AK, Bilcer G, Hey JA, Windisch M. BACE1 Inhibitor CTS21166 (ASP1702) Penetrates Brain and Reduces Aβ Pathology in a Transgenic Mouse Model of Advanced AD. Presented at the International Con-ference on Alzheimer's Disease (ICAD), Chicago, IL, 2008.
75. Bilcer G, Koelsch G, Swanson L, Yu J, Li A, Turner R, Weerasena V, Dehdarani M, Tang J, Ghosh AK, Hey JA. Pharmacological Profile of Bace1 Inhibitor CTS21166 (ASP1702). Presented at the International Conference on Alzheimer's Disease (ICAD), Chicago, IL, 2008.
76. Shitaka Y, Yarimizu J, Nagakura A, Mitani Y, Takami S, Miyake A, Hamakawa N, Hey JA, Koelsch G, Bilcer G, Matsuoka N. Oral Administration of the BACE1 Inhibitor CTS21166 (ASP1702) Improves Cognition and Reduces Brain Aβ in Tg2576 Transgenic Mice. Presented at the Inter-national Conference on Alzheimer's Disease (ICAD), Chicago, IL, 2008.
77. Miyamoto M, Matsui J, Fukumoto H, Tarui N. Preparation of 2-[2-amino-or 2-(N-heterocyclyl) ethyl]-6-(4-biphenylylmethoxy)tetralin derivatives as β-secretase inhibitors. PCT Int Appl WO2001087293A1; 2001.
78. Cole DC, Manas ES, Stock JR, Condon JS, Jennings LD, Aulabaugh A, Chopra R, Cowling R, Ellingboe JW, Fan KY, Harrison BL, Hu Y, Jacobsen S, Jin G, Lin L, Lovering FE, Malamas MS, Stahl ML, Strand J, Sukhdeo MN, Svenson K, Turner MJ, Wagner E, Wu J, Zhou P and Bard J. Acylguanidines as small-molecule beta-secretase inhibitors. J Med Chem 2006; 49: 6158-6161.
79. Baxter EW, Conway KA, Kennis L, Bischoff F, Mercken MH, Winter HL, Reynolds CH, Tounge BA, Luo C, Scott MK, Huang Y, Braeken M, Pieters SM, Berthelot DJ, Masure S, Bruinzeel WD, Jordan AD, Parker MH, Boyd RE, Qu J, Alexander RS, Brenneman DE and Reitz AB. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem 2007; 50: 4261-4264.
80. Geschwindner S, Olsson LL, Albert JS, Deinum J, Edwards PD, de Beer T and Folmer RH. Discovery of a novel warhead against beta-secretase through fragment-based lead generation. J Med Chem 2007; 50: 5903-5911.
81. Edwards PD, Albert JS, Sylvester M, Aharony D, Andisik D, Callaghan O, Campbell JB, Carr RA, Chessari G, Congreve M, Frederickson M, Folmer RH, Geschwindner S, Koether G, Kolmodin K, Krumrine J, Mauger RC, Murray CW, Olsson LL, Patel S, Spear N and Tian G. Application of frag-ment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J Med Chem 2007; 50: 5912-5925.
82. Congreve M, Aharony D, Albert J, Callaghan O, Campbell J, Carr RA, Chessari G, Cowan S, Ed-wards PD, Frederickson M, McMenamin R, Murray CW, Patel S and Wallis N. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. J Med Chem 2007; 50: 1124-1132.
83. Huang D, Luthi U, Kolb P, Edler K, Cecchini M, Audetat S, Barberis A and Caflisch A. Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations. J Med Chem 2005; 48: 5108-5111.
84. Huang D, Luthi U, Kolb P, Cecchini M, Barberis A and Caflisch A. In silico discovery of beta-secretase inhibitors. J Am Chem Soc 2006; 128: 5436-5443.
85. Godemann R, Madden J, Kramer J, Smith M, Fritz U, Hesterkamp T, Barker J, Hoppner S, Hallett D, Cesura A, Ebneth A and Kemp J. Fragment-based discovery of BACE1 inhibitors using functional assays. Biochemistry 2009; 48: 10743-10751.
86. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH and Nave KA. Axonal neuregulin-1 regulates myelin sheath thickness. Science 2004; 304: 700-703.
87. Nave KA and Salzer JL. Axonal regulation of myelination by neuregulin 1. Curr Opin Neurobiol 2006; 16: 492-500.
88. Mei L and Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008; 9: 437-452.
89. Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB, Trapp BD and Yan R. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J 2008; 22: 2970-2980.
90. Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, Lee VM, Woolf CJ and Kovacs DM. BACE1 regulates volt-age-gated sodium channels and neuronal activ-ity. Nat Cell Biol 2007; 9: 755-764.
91. Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper B, Saf-tig P and Nukina N. beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem 2005; 280: 23009-23017.
92. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of volt-age-gated sodium channels. Neuron 2000; 26: 13-25.
93. Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG and Yan R. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci 2010; 30: 8819-8829.
94. Isom LL. Beta subunits: players in neuronal hy-perexcitability? Novartis Found Symp 2002; 241: 124-138; discussion 138-143, 226-132.